Computational design, functional analysis and antigenic epitope estimation of a novel hybrid of 12 peptides of hirudin and reteplase

Journal of Molecular Modeling

Volumn 21, Issue 9, 2015, Pages

  Cai, Yingting ^a   Bao, Jingxiao ^b   Lao, Xingzhen ^b   Zheng, Heng ^b   Chen, Jianhua ^b   Yu, Rong ^a  

^a SICHUAN UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Antigenic epitope estimation; C terminal 12 residue of hirudin PA; Function analysis; Reteplase; Three dimensional structure prediction

Indexed keywords

EPITOPE; HIRUDIN; HYBRID PROTEIN; RETEPLASE; HIRUDIN DERIVATIVE; HIRUDIN PA; RECOMBINANT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR;

AMINO ACID SEQUENCE; ARTICLE; ATOM; CARBOXY TERMINAL SEQUENCE; CONFORMATION; DRUG DESIGN; HYDROPHILICITY; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; SEQUENCE HOMOLOGY; SIMULATION; CHEMISTRY; COMPUTER PROGRAM; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MOLECULAR DYNAMICS; PROTEIN CONFORMATION;

AMINO ACID SEQUENCE; EPITOPES; HIRUDINS; HUMANS; MOLECULAR DYNAMICS SIMULATION; PROTEIN CONFORMATION; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; SOFTWARE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84939233664     PISSN: 16102940     EISSN: 09485023     Source Type: Journal    
DOI: 10.1007/s00894-015-2774-2     Document Type: Article

References (36)

1. Kim AS, Johnston SC (2011) Global variation in the relative burden of stroke and ischemic heart disease. Circulation 124(3):314–323
2. Gaziano TA (2007) Reducing the growing burden of cardiovascular disease in the developing world. Health Aff 26(1):13–24
3. Dohi T, Daida H (2010) Change of concept and pathophysiology in acute coronary syndrome. Nihon Rinsho 68(4):592–596
4. Stam J (2005) Thrombosis of the cerebral veins and sinuses. N Engl J Med 352(17):1791–1798
5. Tsujita K, Kaikita K, Soejima H, Sugiyama S, Ogawa H (2010) Acute coronary syndrome-initiating factors. Nihon Rinsho 68(4):607–614
6. Metz BK, White HD, Granger CB, Simes RJ, Armstrong PW, Hirsh J, Fuster V, MacAulay CM, Califf RM, Topol EJ (1998) Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators. J Am Coll Cardiol 31(7):1493–1498
7. Ocava LC, Singh M, Malhotra S, Rosenbaum DM (2006) Antithrombotic and thrombolytic therapy for ischemic stroke. Clin Geriatr Med 22(1):135–154
8. Rudd MA, George D, Johnstone MT, Moore RT, Collins L, Rabbani LE, Loscalzo J (1992) Effect of thrombin inhibition on the dynamics of thrombolysis and on platelet function during thrombolytic therapy. Circ Res 70(4):829–834
9. Gao L, Zhang C, Li L, Liang L, Deng X, Wu W, Su Z, Yu R (2012) Construction, expression and refolding of a bifunctional fusion protein consisting of C-terminal 12-residue of hirudin-PA and reteplase. Protein J 31(4):328–336
10. Yenari MA, Lee LK, Beaulieu C, Sun GH, Kunis D, Chang D, Albers GW, Moseley ME, Steinberg GK (1998) Thrombolysis with reteplase, an unglycosylated plasminogen activator variant, in experimental embolic stroke. J Stroke Cerebrovasc Dis 7(3):179–186
11. Martin U, Fischer S, Kohnert U, Lill H, Rudolph R, Sponer G, Stern A, Strein K (1990) Properties of a novel plasminogen activator (BM 06.022) produced in Escherichia coli. Z Kardiol 79(S3):167–170
12. Dormiani K, Khazaie Y, Sadeghi HM, Rabbani M, Moazen F (2007) Cloning and expression of a human tissue plasminogen activator variant: K2S in Escherichia coli. Pak J Biol Sci 10(6):946–949
13. Smalling RW (1997) Pharmacological and clinical impact of the unique molecular structure of a new plasminogen activator. Eur Heart J 18:F11–F16
14. Abdualkader AM, Ghawi AM, Alaama M, Awang M, Merzouk A (2013) Leech therapeutic applications. Indian J Pharm Sci 75(2):127–137
15. Lazar JB, Winant RC, Johnson PH (1991) Hirudin: amino-terminal residues play a major role in the interaction with thrombin. J Biol Chem 266(2):685–688
16. Pötzsch B (2013) Anticoagulation. Med Klin Intensivmed Notfmed 108(4):325–334
17. Markwardt F (1994) The development of hirudin as an antithrombotic drug. Thromb Res 74(1):1–23
18. Rydel TJ, Ravichandran KG, Tulinsky A, Bode W, Huber R, Roitsch C, Fenton JW 2nd (1990) The structure of a complex of recombinant hirudin and human alpha-thrombin. Science 249(4966):277–280
19. Bommarius AS, Sohn M, Kang Y, Lee JH, Realff MJ (2014) Protein engineering of cellulases. Curr Opin Biotechnol 29C:139–145
20. Janzen WP, Bernasconi P (2009) High throughput screening. Methods and protocols, 2nd edn. Preface. Methods Mol Biol 565:v–vii
21. Vasserot AP, Watkins JD (2003) Expanding the clinical utility of therapeutic proteins: activated protein C variants with improved pharmacological properties. Trends Pharmacol Sci 24(10):501–504
22. Molecular Operating Environment (MOE) 2009.10 (2009) Chemical Computing Group, Montreal, Canada, https://www.chemcomp.com/
23. Law RHP, Caradoc-Davies T, Cowieson N, Horvath AJ, Quek AJ, Encarnacao JA, Steer D, Cowan A, Zhang Q, Lu BGC, Pike RN, Smith AI, Coughlin PB, Whisstock JC (2012) The x-ray crystal structure of full-length human plasminogen. Cell Rep 1(3):185–190
24. Case DA, Darden TA, Cheatham TE III et al (2012) Amber 12.0. University of California, San Francisco
25. Daniel RR, Cheatham TE III, PTRAJ, CPPTRAJ (2013) Software for processing and analysis of molecular dynamics trajectory data. J Chem Theory Comput 9(7):3084–3095
26. Hopp TP, Woods KR (1981) Prediction of protein antigenic determinants from amino acid sequences. Proc Natl Acad Sci USA 78(6):3824–3828
27. Janin J (1979) Surface and inside volumes in globular proteins. Nature 277(5696):491–492
28. Zimmerman JM, Eliezer N, Simha R (1968) The characterization of amino acid sequences in proteins by statistical methods. J Theor Biol 21(2):170–201
29. Karplus PA, Schulz GE (1985) Prediction of chain flexibility in proteins. Naturwissenschaften 72:212–213
30. Geourjon C, Deléage G (1995) SOPMA: significant improvements in protein secondary structure prediction by consensus prediction from multiple alignments. Comput Appl Biosci 11(6):681–684
31. Kolaskar AS, Tongaonkar PC (1990) A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett 276(1–2):172–174
32. Bryson CJ, Jones TD, Baker MP (2010) Prediction of immunogenicity of therapeutic proteins: validity of computational tools. BioDrugs 24(1):1–8
33. Yang X, Yu X (2009) An introduction to epitope prediction methods and software. Rev Med Virol 19(2):77–96
34. De Groot AS, Moise L (2007) Prediction of immunogenicity for therapeutic proteins: state of the art. Curr Opin Drug Discov Devel 10(3):332–340
35. Tong JC, Tan TW, Ranganathan S (2007) Methods and protocols for prediction of immunogenic epitopes. Brief Bioinform 8(2):96–108
36. Gao L, Yu R (2008) RP-HPLC purification for primary structure confirmation of 12 peptides of hirudin and reteplase fusion protein. Food Drug 10(1):8–12